Exposure to Food Additive Emulsifiers Linked to Risk for Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
MONDAY, May 6, 2024 -- Exposure to food additive emulsifiers is associated with an increased risk for type 2 diabetes, according to a study published in the May issue of The Lancet Diabetes & Endocrinology.
Clara Salame, Ph.D., from the Université Sorbonne Paris Nord and Université Paris Cité, and colleagues analyzed data from 104,139 adults enrolled in the French NutriNet-Santé prospective cohort study to examine the association between exposures to food additive emulsifiers and risk for type 2 diabetes. Dietary intakes were assessed over three nonconsecutive days every six months. Multiple food composition databases and ad-hoc laboratory assays were used to assess exposure to additive emulsifiers.
During a mean follow-up duration of 6.8 years, 1,056 participants were diagnosed with type 2 diabetes. The researchers found that the risk for type 2 diabetes was increased in association with total intakes of carrageenans, carrageenans gum (E407), tripotassium phosphate (E340), acetyl tartaric acid esters of monoglycerides and diglycerides of fatty acids (E472e), sodium citrate (E331), guar gum (E412), gum arabic (E414), and xanthan gum (E415; hazard ratios, 1.03, 1.03, 1.15, 1.04, 1.04, 1.11, 1.03, and 1.08, respectively, per increment of 100 mg, 100 mg, 500 mg, 100 mg, 500 mg, 500 mg, 1,000 mg, and 500 mg per day, respectively).
"These findings provide the first epidemiological insight about the potential involvement in the development of type 2 diabetes of emulsifier additives that are ubiquitous in western diets and consumed daily by millions of children and adults worldwide," the authors write.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.